HLA Typing from FFPE Blocks

At a glance:

• Quick answer: HLA typing from FFPE blocks—can it work?
• Why FFPE is challenging for long-read HLA typing
• Should researchers submit FFPE blocks or extracted DNA?
• What information should be provided for FFPE feasibility review?
• What QC matters for FFPE-derived DNA?
• When an alternative sample may be better
• Limitations and RUO note
• FAQ
• Next steps: request an FFPE feasibility review
• Author

FFPE blocks may be considered for HLA typing only after a feasibility review, because formalin fixation can fragment and chemically modify DNA. That matters for long-read HLA typing: long-read methods benefit from longer intact molecules, while FFPE often yields shorter, damaged fragments that can reduce phasing power and increase the chance of ambiguous or incomplete results.

If your core question is "Do I need to send extracted DNA, or can CD Genomics extract DNA from my FFPE blocks?" the practical answer is: both pathways may be possible, but which one is advisable depends on what your FFPE tissue can realistically yield after deparaffinization, digestion, and QC. A feasibility-first workflow helps prevent failed extraction, low-complexity libraries, or HLA calls that are technically correct but not at the resolution you need. In practical terms, this is an FFPE DNA extraction and FFPE DNA quality control question as much as it is an HLA question—and it's where most long-read HLA typing limitations show up first.

Key Takeaway: Treat FFPE as a project input that requires triage, not as a guaranteed-compatible sample type—especially when the end goal is long-read phasing or broader MHC haplotyping.

Quick answer: HLA typing from FFPE blocks—can it work?

Sometimes—under research-use-only conditions—but not reliably without sample-specific review. FFPE processing is intentionally harsh on biomolecules: formalin introduces crosslinks and chemical modifications, and storage plus handling typically increases fragmentation over time. Reviews of FFPE sequencing show that these effects reduce amplifiable template and increase artifacts relative to fresh/frozen material, making performance highly variable from block to block (and even from region to region within a block), as summarized in the Nucleic Acids Research review "A critical spotlight on the paradigms of FFPE-DNA sequencing" (2023) and the PMC review "Use of FFPE-derived DNA in next generation sequencing" (2019) (NAR, 2023; PMC, 2019).

For HLA typing, the feasibility question is two-layered:

1. Can we obtain enough usable DNA from the block? (yield, inhibitors, amplifiability)
2. Is the resulting DNA compatible with the long-read strategy needed for your requested resolution? (fragment length distribution vs required span for phasing/assembly)

That's why the correct starting point is usually feasibility review + QC, not a yes/no promise.

Why FFPE is challenging for long-read HLA typing

Long-read HLA typing is attractive because longer reads can reduce allele ambiguity by spanning more polymorphisms and by supporting phasing across a gene or even a broader MHC haplotype. Classic discussions of HLA ambiguity emphasize that ambiguity often arises from incomplete interrogation of polymorphisms or lack of phase; long reads directly address that phasing gap (Measuring Ambiguity in HLA Typing Methods, 2012; IPD-IMGT/HLA ambiguity help).

FFPE complicates this because it pushes your DNA in the opposite direction: shorter molecules, more damage, and more variability.

What formalin fixation does to DNA (and why long reads care)

At a mechanistic level, formalin fixation and downstream processing can lead to:

• Fragmentation (shorter DNA pieces): reduces the availability of long templates.
• Crosslinking (DNA–DNA and DNA–protein links): lowers effective extraction yield and can inhibit enzymatic steps.
• Base damage / chemical modification (e.g., deamination, abasic sites): increases the risk of sequencing artifacts and can reduce polymerase performance.

These issues are widely described in sequencing-focused FFPE reviews and method papers (see the same NAR and PMC reviews above). Importantly, they are not purely "quality" issues—they directly affect whether a long-read workflow can access the long-range information that makes long reads valuable in the HLA region.

Why the HLA region amplifies the impact of FFPE damage

HLA typing is not "just another locus." HLA genes are highly polymorphic, and the surrounding MHC region is complex. In practice, long-read assays are valuable here because they can support MHC phasing across more of the region when DNA molecules are long enough. Ambiguity can occur when the sequenced region does not include the positions that distinguish alleles, or when variants cannot be phased to the same haplotype. A Frontiers review on NGS-based HLA typing (2018) discusses how phasing limitations contribute to ambiguity even with sequencing-based methods (Frontiers, 2018).

When FFPE shortens molecules:

• You may lose the ability to span informative variant combinations.
• You may need to fall back to shorter-amplicon strategies (if feasible), which can reintroduce ambiguity.
• Coverage can become uneven due to damage and inhibitor effects, increasing the risk of dropouts.

Workflow view: where feasibility gates belong

FFPE-derived DNA should be reviewed for quality and suitability before long-read HLA typing.

In a long-read context, "feasibility" is not a single metric. It's a decision gate that weighs:

• what your FFPE can yield (quantity + usable fraction),
• what your requested resolution requires (span/phasing), and
• what failure modes are acceptable for your study design.

Should researchers submit FFPE blocks or extracted DNA?

If your team is deciding between shipping FFPE blocks vs shipping extracted DNA, treat it as a control question: Where do you want the highest leverage over sample quality and documentation—your lab, or the service workflow?

A practical approach is:

• If you already have extracted DNA plus credible QC (concentration + fragment distribution + amplifiability), you can often accelerate feasibility assessment.
• If you do not have extraction capacity—or you want a single accountable workflow—submitting FFPE blocks/sections may be reasonable, but extraction workflow details and feasibility criteria should be confirmed with the CD Genomics service team.

For service scope and long-read HLA typing context, you can refer to the CD Genomics long-read HLA typing service (RUO).

Table 1. Submit FFPE block vs extracted DNA (what changes)

Interpretation: Neither route is universally "better." The decision is mainly about control and transparency. With FFPE, the extraction step is often the highest-variance part of the workflow; whichever party performs it should be prepared to document what was done and what QC indicates about usable template.

What information should be provided for FFPE feasibility review?

If you want a fast feasibility assessment (and a quote-ready response), the most helpful information is not a narrative—it's structured metadata.

Below is a feasibility-oriented checklist of what to send. Note that we are intentionally not specifying a universal "acceptable block age," a universal "number of sections," or numeric QC cutoffs here, because those are project- and method-dependent and should be confirmed by the service team for your specific design.

Table 2. FFPE factors to report (and why they matter)

Interpretation: For FFPE, feasibility is a systems problem: pre-analytics, available material, and study goal all interact. A block might be "fine" for a short-amplicon question but "high risk" for a long-read phasing goal. Providing structured metadata lets the service team align method choice to your actual end point.

A decision checklist you can use before contacting a service team

Use the following to quickly triage whether you should prepare for a pilot study, gather more QC, or switch sample types.

Table 3. FFPE feasibility checklist (project triage)

Interpretation: If you cannot answer the first two items, start by collecting basic QC (or plan for extraction + QC as a distinct feasibility stage). If long-range phasing is a must-have outcome, consider whether a non-FFPE sample type is available for at least a subset of cases.

What QC matters for FFPE-derived DNA?

FFPE DNA QC should answer three questions:

1. How much double-stranded DNA do we have? (quantity)
2. How broken is it? (fragment length distribution)
3. Will it actually work in enzymatic steps? (amplifiability and inhibition)

A recurring theme in FFPE sequencing literature is that spectrophotometry alone is not sufficient for determining usable FFPE DNA because it can overestimate functional template. Sequencing-focused reviews recommend combining fluorometric quantification with integrity and qPCR-based QC (PMC, 2019; NAR, 2023).

QC categories (what they mean in practice)

• Concentration / yield (fluorometric): A dsDNA-specific assay gives a better estimate of usable dsDNA than absorbance-based measures.
• Purity / carryover: Contaminants can inhibit polymerases and ligation; purity ratios can flag issues but do not guarantee amplifiability.
• Fragment size distribution / integrity: Electrophoretic methods show whether DNA is mostly short smear or retains longer fragments.
• Amplifiability (qPCR): Short-amplicon qPCR is a practical proxy for "will library prep work?" and can also reveal inhibition when internal controls are delayed.

⚠️ Warning: FFPE DNA can look "present" by mass, but behave like it's absent during PCR or library prep. When feasibility is tight, amplifiability matters as much as concentration.

Why QC must be interpreted against the method, not in isolation

Long-read HLA typing can be implemented with different lab strategies (e.g., different enrichment or library approaches). The same FFPE DNA that fails one approach may still support a more fragment-tolerant design—while still limiting long-range phasing. That's why QC is best treated as an input to method selection and expected resolution, not as a universal pass/fail label.

If you're preparing to ship samples, the CD Genomics sample submission guideline is the right place to confirm packaging and submission details for long-read workflows.

When an alternative sample may be better

If the study question allows it, alternative sample types often reduce risk and increase the value you can extract from long reads.

Situations where FFPE is usually high risk for long-read benefit

• You need long-range phasing across longer spans and cannot tolerate reduced span.
• You need high confidence resolution and want to minimize ambiguity.
• Your FFPE tissue is limited and cannot support iteration.

Alternatives to consider (research contexts)

• Fresh-frozen tissue: typically preserves longer DNA fragments better than FFPE.
• Fresh tissue / cell pellet: often supports higher molecular weight DNA extraction.
• Blood / cell line DNA: can provide high-quality gDNA for long-read phasing.
• Previously extracted high-quality DNA: if you already have genomic DNA with QC supporting longer fragments, it's often the fastest path to long-read value.

The key point is not that FFPE can't work—it's that if you have a better option for even a subset of samples, you can use that subset as a benchmark to interpret FFPE-derived results.

Limitations and RUO note

• Research Use Only (RUO): This content and related services are intended for research use and are not for diagnostic procedures.
• No universal FFPE guarantees: FFPE blocks vary widely. Feasibility is influenced by pre-analytical variables and available material.
• Resolution limits are sample-dependent: With fragmented DNA, long-read workflows may lose the long-range information that reduces ambiguity.

FAQ

Can HLA typing be done from FFPE blocks?

Yes—in some research contexts, HLA typing may be possible from FFPE blocks, but it should be treated as a feasibility-gated workflow rather than a guaranteed sample type. Formalin fixation can fragment DNA and introduce chemical changes, and both effects can reduce the amount of usable template and complicate sequencing-based interpretation. Sequencing-focused reviews emphasize that FFPE performance varies substantially between blocks and depends on pre-analytical factors and available material (Use of FFPE-derived DNA in NGS, 2019). For long-read HLA typing, feasibility also depends on whether the DNA fragment distribution supports the span needed for phasing.

Can CD Genomics extract DNA from FFPE blocks?

In many projects, a service team may be able to handle DNA extraction from FFPE material, but the exact workflow and acceptance criteria should be confirmed during feasibility review. If you're contacting CD Genomics about an FFPE HLA typing project, the most helpful step is to describe what you can provide (blocks vs scrolls/slides vs extracted DNA) and include any existing QC. Because FFPE material varies widely, extraction feasibility is best determined case-by-case rather than assumed. If extracted DNA is already available, sharing QC (fragment distribution and amplifiability) can speed up the go/no-go decision.

Is FFPE DNA suitable for long-read HLA typing?

Sometimes, but it is inherently more challenging than high-integrity DNA. Long-read approaches are most valuable when they can span multiple polymorphisms on the same molecule, reducing phasing ambiguity in highly polymorphic loci. FFPE processing often shortens DNA fragments and can introduce lesions that reduce amplifiability and effective library complexity. As a result, FFPE-derived DNA can limit long-range phasing and may increase the chance of incomplete coverage or ambiguous calls. A feasibility workflow that includes QC for fragment size distribution and amplifiability is the safest way to decide whether the long-read strategy aligns with your FFPE material.

What FFPE information should I provide before a quote?

Provide structured metadata that allows feasibility triage. At minimum, include: sample count, tissue type, approximate block age (if known), what material is available (blocks vs sections vs extracted DNA), and your requested HLA loci and resolution. If you have extracted DNA, add concentration, fragment distribution, and any qPCR-based QC that reflects amplifiability or inhibition. This information helps a service team decide whether to start with a pilot subset, whether additional QC is needed, and which long-read strategy is realistic for your goal. If key metadata is missing, feasibility review becomes slower and more uncertain.

Should I use frozen tissue instead of FFPE?

If frozen tissue is available, it is often a lower-risk input for long-read sequencing because DNA integrity is typically better preserved than in FFPE. That matters when your study relies on long-range information (phasing or broader MHC haplotyping) rather than only short local sequence. FFPE may still be usable—especially when it's the only available material—but it should be approached with a feasibility-first mindset and realistic expectations about fragment lengths and potential dropouts. A practical compromise is to include a frozen subset (if possible) as a benchmark to interpret FFPE-derived results.

Can FFPE HLA typing be used clinically?

This article and the referenced services are for research use only and are not intended for clinical diagnosis, clinical decision-making, or patient care. If your project context touches clinical questions (for example, transplantation, treatment, or patient eligibility), you should consult qualified clinical laboratories and appropriate regulatory pathways. In research settings, the role of feasibility review is to ensure that sample limitations (such as FFPE fragmentation and chemical damage) are clearly understood so that results are interpreted within an appropriate non-clinical scope.

Next steps: request an FFPE feasibility review

If you are considering FFPE blocks for long-read HLA typing, the fastest way to get a meaningful answer is to provide feasibility-ready details.

Send FFPE block details, sample number, available DNA/QC information, and requested HLA loci to request an FFPE HLA typing feasibility review.

Author

Dr. Yang H., Senior Scientist, CD Genomics — long-read sequencing and bioinformatics. Dr. Yang focuses on sequencing strategy selection, QC transparency, and feasibility-driven planning for complex genomics projects, including long-read HLA typing workflows and challenging sample types such as FFPE.

LinkedIn: Dr. Yang H. on LinkedIn